Moderna Stock Slides Again Friday: What's Going On?
Bullish strength: 38/100
- Combination therapy reduces risk of recurrence or death by 42%
- Six-month sensitivity analysis shows risk reduction reaches 58%
Bearish strength: 62/100
- Moderna shares plunge over 17% Thursday, extend losses premarket Friday
- Market worries over clinical data for personalized melanoma vaccine
This is automated NewsSignals analysis of third-party reporting, not independent original reporting or investment advice. AI scores are not price predictions.